Group 1 - The core issue revolves around misleading statements made by the company regarding its involvement in the brain-computer interface sector, leading to a regulatory investigation by the China Securities Regulatory Commission (CSRC) [1][4] - The company announced a strategic cooperation framework in early January, claiming its partner was engaged in both invasive and non-invasive technologies, which resulted in a 6.52% increase in stock price and a nearly threefold increase in trading volume on the announcement day [1][4] - Following regulatory scrutiny, the company issued a supplementary announcement clarifying that the partner had no invasive technology and was only in the early stages of non-invasive technology development, revealing significant discrepancies in their disclosures [2][4] Group 2 - Prior to the CSRC's investigation, the Shanghai Stock Exchange had already issued a regulatory warning on January 7, highlighting inaccuracies and incompleteness in the company's disclosures [3][5] - The exchange emphasized the need for the company to provide adequate risk warnings regarding the feasibility and uncertainties of the partnership, as the brain-computer interface is a highly scrutinized market area [5] - The company has been ordered to submit a comprehensive rectification report, with all directors and executives required to confirm their signatures, and to conduct a thorough internal compliance review [5]

Investment Rating - The industry investment rating is optimistic (maintained) [3] Core Insights - Neuralink brings new insights: brain-machine interfaces (BMIs) are expected to become the preferred method for human-machine communication, reaching a broader market [6] - Domestic policies and industry window periods for BMIs resonate, with a significant increase in clinical cases in China [7] - BMIs are deeply integrated with large models and embodied intelligence technologies, significantly accelerating application deployment speed [8] Summary by Sections Neuralink's Development - Neuralink, founded in 2016, has a valuation of over $9 billion as of June 2025, focusing on high-bandwidth invasive BMI technology to enhance communication efficiency [16] - The first product, Telepathy, is expected to be mass-produced in 2026, targeting severe groups with disrupted communication pathways, such as spinal cord injury and ALS patients [9][25] Progress in China's Brain-Machine Interface - The Chinese Brain Plan (2021-2030) is entering a critical implementation phase, with BMIs recognized as a future industry [73] - The Ministry of Industry and Information Technology and other departments issued opinions to promote BMI industry innovation, aiming for significant technological breakthroughs by 2027 and enhanced innovation capabilities by 2030 [75] - Clinical research on invasive BMIs in China has significantly increased, with several institutions entering clinical trial phases [8][41] Integration with AI and Embodied Intelligence - The integration of BMIs with large models enhances generalization capabilities and accelerates application deployment, addressing core bottlenecks in BMIs [8] - The combination of BMIs and embodied intelligence aims to create more powerful physical interfaces for human intentions, with applications in rehabilitation and robotics [8] Market Opportunities - The primary market for BMIs currently lies in the medical field, helping patients communicate and live like ordinary individuals [68] - The potential for BMIs extends beyond medical applications, with future possibilities including enhanced human-AI interaction and control of complex machinery [70]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4][47]. Core Viewpoints - The pharmaceutical market showed a slight increase of 0.14% from February 2 to February 6, with a relative outperformance of 1.47% compared to the CSI 300 index. The report suggests focusing on strong fundamental innovative drug stocks and highlights the potential for recovery in the innovative drug sector [5][16]. - The report emphasizes the significance of molecular glue technology in expanding the druggable target space, particularly for "undruggable targets," and suggests monitoring the progress of related drugs from Yuandong Biotech [3][8]. - The report outlines a positive outlook for the pharmaceutical industry in 2026, driven by technological innovation and performance/valuation recovery, with a focus on innovative drugs, AI medical technology, and the aging population's healthcare needs [36][37]. Summary by Sections Market Performance - The pharmaceutical index increased by 0.14% during the specified week, with 253 stocks rising and 206 falling. Top gainers included Guangshengtang (+29.83%) and Haixiang Pharmaceutical (+18.64%), while major losers included Changshan Pharmaceutical (-15.78%) and Shuanglu Pharmaceutical (-13.95%) [5][16][17][18]. Molecular Glue Technology - Molecular glue targets undruggable proteins, with only about 3.5% of human proteins confirmed as druggable. The report highlights Yuandong Biotech's advancements in this area, particularly their product HP-001, which shows promising clinical data and potential as a "Best-in-Class" treatment [8][12][13]. Investment Recommendations - The report recommends focusing on innovative drug companies such as Heng Rui Pharmaceutical, China Biologic Products, and Yuandong Biotech, as well as companies involved in AI medical technology and healthcare for the aging population [36][39]. Industry Trends - The report identifies key trends such as the acceleration of the aging population, the growth of chronic disease demand, and the increasing importance of commercial insurance in the healthcare payment system. It also notes the potential for new growth drivers from AI and brain-computer interface technologies [36][37]. Valuation Insights - As of February 6, 2026, the overall PE valuation for the pharmaceutical sector is 37.31X, indicating a relatively low historical position. The report suggests that various sub-sectors have differing valuation levels, with some being relatively high and others low [25][32]. Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve in 2026, with a focus on innovative drugs and technologies. It suggests that structural growth opportunities will emerge, particularly in the context of the global healthcare landscape [36][37].

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the benchmark index over the next 6-12 months [33]. Core Insights - Significant breakthroughs in brain-computer interface and quantum communication technologies are expected to accelerate the development of related industrial chains, with a focus on companies such as Jiayuan Technology, iFlytek, Wanda Information, Anheng Information, and Guodun Quantum [4][2]. - The first brain-controlled acupuncture rehabilitation equipment has been successfully implemented, marking a substantial advancement in the medical application of brain-computer interfaces [2][13]. - Shanghai has identified brain-computer interfaces and semiconductors as key future industries, providing strong policy support for their development [15][16]. - The University of Science and Technology of China has achieved major breakthroughs in quantum networking, paving the way for practical quantum communication [17][19]. - Waymo has completed a significant financing round of $16 billion, indicating a new phase of development in the autonomous driving industry [20][21]. Summary by Sections Brain-Computer Interface - The first brain-controlled acupuncture rehabilitation platform, "Shengong-Hua Tuo," has been launched, integrating advanced brain-computer interface technology with traditional acupuncture for personalized treatment [13][14]. - This technology has been validated through space experiments, enhancing its reliability and potential for widespread clinical application [14]. Quantum Communication - The University of Science and Technology of China has made two critical advancements in quantum networking, addressing long-standing challenges in the field and significantly extending the distance for quantum key distribution [17][19]. - These breakthroughs position China as a leader in quantum communication, with implications for national security and information protection [19]. Autonomous Driving - Waymo's recent financing of $16 billion has raised its post-money valuation to $126 billion, reflecting strong growth in its business operations [20]. - The company plans to expand its services to over 20 cities globally, indicating a shift from technology validation to large-scale commercial operations in the autonomous driving sector [21].

Core Insights - The brain-computer interface (BCI) industry is transitioning from "technology validation to early commercialization," with the medical rehabilitation sector being the first to achieve large-scale implementation due to rigid demand and policy support [1] - The report suggests focusing on three categories of targets: leading companies in non-invasive product commercialization, clinical breakthrough targets in invasive/interventional technologies, and core component suppliers in the industry [1] Market Space - The global BCI market is projected to reach $2.62 billion in 2024, with a compound annual growth rate (CAGR) of 17.35% from 2025 to 2034, potentially exceeding $12.4 billion by 2034 [2] - The domestic market is also expanding steadily, with an expected size of 3.2 billion yuan in 2024, where non-invasive products will account for 82%. The China Electronic Information Industry Development Research Institute forecasts the domestic market to grow to 5.58 billion yuan by 2027 [2] Core Technology - The industry faces significant technological barriers concentrated in three areas: signal acquisition, decoding algorithms, and neural stimulation [3] - Leading overseas companies are advancing in clinical applications, with Neuralink completing 21 human implant surgeries and Synchron's vascular interventional BCI product receiving FDA approval. Domestic companies are catching up, achieving global breakthroughs such as the "Beinao No. 1" 128-channel semi-invasive system and the first interventional BCI human trial [3] Policy and Ecosystem - Continuous policy support is evident, with national "14th Five-Year" and "15th Five-Year" plans highlighting BCI as a key development area. 29 provinces and cities, including Zhejiang and Hubei, have included BCI rehabilitation projects in their medical insurance payment scope, accelerating clinical adoption [4] - The upstream core component localization process is speeding up, with domestic analog chips showing a 60% reduction in power consumption compared to similar overseas products. Downstream applications in medical rehabilitation and consumer electronics are beginning to form initial scales [4]

Group 1: Quantum Technology - The team from the University of Science and Technology of China achieved significant breakthroughs in scalable quantum networks, including the construction of a basic module for scalable quantum repeaters and the realization of device-independent quantum key distribution (DI-QKD) over a distance of 100 kilometers, improving previous international experimental levels by over two orders of magnitude [4][5]. - The successful implementation of a quantum repeater with an entanglement lifetime of 550 milliseconds, exceeding the entanglement establishment time of 450 milliseconds, marks a critical advancement in quantum communication, enabling the construction of a kilometer-scale quantum internet [5]. Group 2: Biomanufacturing - The Shenzhen Advanced Institute of Technology developed a programmable integration platform for functional molecules, which opens up new applications in biomanufacturing, biosensing, and flexible electronics [6][7]. - OpenAI partnered with Ginkgo Bioworks to create an AI-driven automated experimental system that significantly reduces the production costs of cell-free protein synthesis (CFPS) by approximately 40% and reagent costs by 57% [8]. Group 3: Hydrogen Energy and Nuclear Fusion - The China Energy Construction Group's Songyuan hydrogen energy industrial park project has produced over 10,000 tons of green ammonia and received EU certification, validating the integrated commercial model of "green electricity - green hydrogen - green ammonia" [9][10]. - Shenzhen Energy signed a contract for a 505MW wind-solar hydrogen project with a total investment of approximately 8 billion, covering both upstream and downstream sectors [12]. Group 4: Brain-Computer Interfaces - The company Borui Kang has initiated the process for its initial public offering (IPO), marking a transition of invasive brain-computer interface technology from research to commercialization [13][15]. - A research team from the Chinese Academy of Sciences developed a novel optogenetic technique for visual brain-computer interfaces, enabling high-precision, long-term optical stimulation of the visual cortex, representing a significant advancement in sensory information input [16][18]. Group 5: Embodied Intelligence - Microsoft Research introduced a new robot model, Rho-alpha, which integrates multimodal perception capabilities, including visual, language, and tactile data, aimed at enhancing the application of embodied intelligence in unstructured environments [21]. Group 6: 6G and Commercial Space - A research team from Beijing University of Posts and Telecommunications made significant progress in 6G channel modeling, with their work being included in the international 6G standard framework by 3GPP [22]. - The U.S. Federal Communications Commission (FCC) accepted SpaceX's application for an orbital data center, which aims to establish a satellite constellation of up to 1 million satellites to support advanced AI models and applications [25]. Group 7: Future Industry Catalysts - A table summarizing key catalytic events for six future industries in 2026 was provided, highlighting important milestones and conferences that investors should track [26][27].

Group 1 - The article highlights Xi Jinping's visit to the National Innovation Park in Beijing, focusing on the application of information technology and the acceleration of building an international technology innovation center [1] - During the visit, Xi Jinping engaged in discussions with representatives from research institutions and technology companies, emphasizing the importance of technological innovation [1] Group 2 - The article mentions significant developments in commercial aerospace and breakthroughs in brain-computer interfaces, indicating positive impacts on the market [7] - It also notes a major signal regarding a 49 trillion yuan giant that is undergoing bulk share reductions, which could influence market dynamics [7] - Additionally, there are alerts about several major stocks in the A-share market that are facing urgent risk warnings [7]

责编：罗晓霞 校对： 杨舒欣 百万用户都在看 央行等八部门，重磅发布！商业航天，大消息！算力，利好！脑机接口，重大突破！影响一周市场的 十大消息 利好来了！刚刚，福建重磅发布！ 重大信号！49万亿巨头，批量减持！ A股突发！多只大牛股，紧急提示风险！ 盘中，大幅拉升！重大突破！量子科技，突传利好！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 香港特区高等法院9日宣判，黎智英因两项串谋勾结外国势力罪及一项串谋发布煽动刊物罪被判监禁20 年。 来源：新华社 券中社 × 券商中国 券 中 社 扫码下载券中社APP 扫码关注券商中国公众号 quanshangcn qzs.stcn.com 舞中 券中社APP 券 商 中 国 是 证 券 市 场 权 威 媒 体 《 证 券 时 报 》 旗 下 新 媒 体 , 券 商 中 国 对 该 平 台 所 刊 载 的 原 创 内 容 享 有 著 作 权 , 未 经 授 权 禁 止 转 载 ， 否 则 将 追 究 相 应 法 律 责 任 。 看券商中国 知天下财经 F ...

Core Insights - Neurotechnology is transitioning from basic research to clinical application and industrialization, driven by the increasing burden of neurological diseases, rapid breakthroughs in brain science, and the deep integration of engineering technology and computational capabilities [1] - The first Global NeuroTech Conference 2026 will be held on June 12, 2026, at the Zhongguancun Conference Center, aiming to connect brain science research, engineering technology, clinical applications, corporate innovation, capital, and regulation [1] - The conference will feature the release of the "2026 Global Neurotechnology Innovation White Paper," which will focus on various key areas including brain-computer interfaces, neural modulation technologies, and AI in computational neuroscience [2] Section Summaries Section 1: White Paper Release - The conference will officially release the "2026 Global Neurotechnology Innovation White Paper," focusing on areas such as brain-computer interfaces (BCI), neural modulation technologies (DBS, TMS, VNS, SCS), neuroimaging, and clinical translation paths for neurotechnology [2] Section 2: Innovation Awards - Multiple annual awards will be presented at the conference, evaluating innovations in neurotechnology based on originality, clinical potential, industrial value, and long-term development capabilities, emphasizing collaborative innovation between foundational breakthroughs and engineering realizations [3] Section 3: Thematic Forums - The forums will cover cutting-edge topics in neurotechnology, including brain-computer interfaces, neural modulation technologies, neuroimaging, AI in neuroscience, and discussions on the ethical and commercial pathways for neurotechnology [4] Audience Composition - The conference will target a diverse audience, including neurotechnology companies, clinical experts, researchers, investors, and regulatory professionals, emphasizing a forward-looking and research-oriented approach [8][10] Sponsorship Opportunities - The conference offers sponsorship opportunities for neurotechnology enterprises and institutions, ensuring compliance and sustainable collaboration while maintaining academic rigor and industry depth [7] Conference Details - The conference is expected to host around 800 participants, providing a platform for showcasing cutting-edge technologies and fostering connections between research, clinical, and engineering resources [9]

Core Insights - Shenzhen aims to consolidate and enhance its manufacturing advantages, targeting a growth of over 6% in industrial added value by 2026 [1] - The city plans to implement the "20+8" strategic emerging industry clusters and future industry policy system 3.0 this year, focusing on new generation electronic information, new energy vehicles, semiconductors, and integrated circuits [1] - Shenzhen is set to accelerate the development of artificial intelligence, with a target of over 10% growth in the AI industry cluster's added value this year [1] Manufacturing and Industry Development - Shenzhen will establish and utilize projects such as BYD's global R&D center and accelerate the advancement of various technology parks and projects [1] - The city aims to seize new opportunities in low-altitude economy, aerospace, biomedicine, and high-performance materials [1] Artificial Intelligence Initiatives - Shenzhen plans to strengthen the construction of a fully autonomous AI software and hardware ecosystem, focusing on core technologies such as algorithm theory, model architecture, intelligent chips, and robotics [1] - The city will enhance the use of national AI infrastructure and supercomputing centers to create a world-class intelligent integration paradigm [1] - There will be a deepened implementation of the AI terminal industry development action plan [1] Software and Information Technology Services - Shenzhen will accelerate the development of software and information technology services, aiming for a revenue growth of over 10% this year [1] - The city will promote the large-scale application of domestic operating systems and open-source technologies in various sectors, including smart home appliances and industrial applications [1]